Loading...
XSHE000566
Market cap784mUSD
Jan 10, Last price  
4.35CNY
1D
-3.97%
1Q
12.99%
Jan 2017
-65.77%
Name

Hainan Haiyao Co Ltd

Chart & Performance

D1W1MN
XSHE:000566 chart
P/E
—
P/S
3.89
EPS
—
Div Yield, %
2.42%
Shrs. gr., 5y
-0.48%
Rev. gr., 5y
-9.77%
Revenues
1.48b
-16.89%
225,421,399210,271,048213,587,764241,718,975386,651,529517,205,207613,189,625721,847,493951,387,5331,052,288,0301,384,750,9601,678,281,8341,543,980,3801,824,521,5942,471,770,2212,445,289,3062,200,313,9772,059,062,7611,779,052,1931,478,580,692
Net income
0k
-100.00%
24,982,71921,744,54324,552,981042,731,70765,596,16734,338,628105,075,28777,252,79093,844,973162,784,442195,271,278164,628,97786,626,637119,569,2030002,377,0500
CFO
104m
-27.17%
36,328,49426,315,56330,514,00406,813,46578,837,76151,608,62457,776,3812,367,913181,805,14714,983,199141,599,9840526,479,214000108,223,441142,170,662103,548,849
Dividend
Aug 15, 20180.1 CNY/sh
Earnings
May 23, 2025

Profile

Hainan Haiyao Co., Ltd. manufactures and sells pharmaceutical products and medical devices in China and internationally. The company develops intermediates, APIs, innovative chemical drugs, modern Chinese medicines, biological drugs, cellular immunity products, and high-end medical devices. It offers its products in various forms, such as pills, tablet granules, tincture fluid extracts, powders, syrups, soft capsule raw materials, powder injections, and health foods in various antibiotic series, gastrointestinal medication series, anti-tumor medicine series, cochlear implant series, etc.; and vitamin C for injection scurvy, idiopathic methemoglobinemia, etc. The company also provides internet medical treatment and medical services. Hainan Haiyao Co., Ltd. was founded in 1965 and is headquartered in Haikou, China.
URL
http://www.haiyao.com.cn/
IPO date
May 25, 1994
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,478,581
-16.89%
1,779,052
-13.60%
Cost of revenue
1,410,577
1,630,432
Unusual Expense (Income)
NOPBT
68,004
148,621
NOPBT Margin
4.60%
8.35%
Operating Taxes
16,780
Tax Rate
24.67%
NOPAT
51,224
148,621
Net income
2,377
 
Dividends
(139,187)
Dividend yield
2.37%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,787,109
2,738,663
Long-term debt
902,759
660,871
Deferred revenue
77,681
72,466
Other long-term liabilities
504,631
268,583
Net debt
1,364,687
1,999,021
Cash flow
Cash from operating activities
103,549
142,171
CAPEX
(210,688)
Cash from investing activities
(82,434)
393,959
Cash from financing activities
(42,841)
(761,630)
FCF
486,924
(142,204)
Balance
Cash
932,995
974,527
Long term investments
392,187
425,985
Excess cash
1,251,252
1,311,560
Stockholders' equity
(438,805)
1,695,780
Invested Capital
5,833,357
4,731,742
ROIC
0.97%
3.17%
ROCE
1.25%
2.45%
EV
Common stock shares outstanding
1,297,060
1,297,365
Price
4.52
5.85%
4.27
-18.67%
Market cap
5,862,711
5.83%
5,539,749
-18.67%
EV
7,365,313
7,711,156
EBITDA
235,133
301,868
EV/EBITDA
31.32
25.54
Interest
179,111
218,196
Interest/NOPBT
263.38%
146.81%